Affitech A/S, a therapeutic antibody company that was created in May 2009 by the merger of a privately-owned Norwegian company and Pharmexa A/S of Denmark, plans to raise new equity capital this year to finance its antibody programme. ---Subscribe to MedNous to access this article---
